NCT00460265View on ClinicalTrials.gov

Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

658

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2012

Conditions
Recurrent and/or Metastatic Head and Neck Cancer
Interventions
DRUG

ARM 2

Subjects will receive Cisplatin plus 5FU

DRUG

ARM 1

Subjects will receive Panitumumab plus cisplatin and 5FU

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY